Chinese Journal of Antituberculosis ›› 2019, Vol. 41 ›› Issue (1): 88-94.doi: 10.3969/j.issn.1000-6621.2019.01.018
• Original Articles • Previous Articles Next Articles
Yu-jie ZHAO1,*,Kai YAN2,Jin-ou CHEN3,Ling LI3,Yun-bin YANG3,Lin XU3()
Received:
2018-07-26
Online:
2019-01-10
Published:
2019-01-09
Contact:
Yu-jie ZHAO
E-mail:xulinth@hotmail.com
Yu-jie ZHAO,Kai YAN,Jin-ou CHEN,Ling LI,Yun-bin YANG,Lin XU. Analysis of the quality of life and its influencing factors in patients with multidrug-resistant tuberculosis[J]. Chinese Journal of Antituberculosis, 2019, 41(1): 88-94. doi: 10.3969/j.issn.1000-6621.2019.01.018
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2019.01.018
社会学特征 | MDR-TB组(例) | 构成比(%) | 对照组(例) | 构成比(%) |
---|---|---|---|---|
性别 | ||||
男 | 38 | 82.6 | 38 | 82.6 |
女 | 8 | 17.4 | 8 | 17.4 |
年龄(岁) | ||||
<20 | 3 | 6.5 | 3 | 6.5 |
20~ | 27 | 58.7 | 27 | 58.7 |
40~ | 14 | 30.4 | 14 | 30.4 |
60~ | 2 | 4.4 | 2 | 4.4 |
职业 | ||||
工人 | 2 | 4.3 | 6 | 13.0 |
农民 | 26 | 56.5 | 22 | 47.8 |
国家单位职工 | 1 | 2.2 | 4 | 8.7 |
其他(个体户、待业等) | 17 | 37.0 | 14 | 30.5 |
户口所在地 | ||||
城市 | 7 | 15.2 | 8 | 17.4 |
农村 | 39 | 84.8 | 38 | 82.6 |
家庭月收入(元) | ||||
<1000 | 11 | 23.9 | 5 | 10.9 |
1000~ | 22 | 47.8 | 11 | 23.9 |
3000~ | 10 | 21.7 | 6 | 13.0 |
5000~ | 3 | 6.6 | 24 | 52.2 |
医保 | ||||
有 | 38 | 82.6 | 42 | 91.3 |
无 | 8 | 17.4 | 4 | 8.7 |
因素 | 生命质量总得分(分, | 统计检验值 | P值 |
---|---|---|---|
性别 | t=-1.17 | 0.248 | |
男 | 150.76±17.05 | ||
女 | 158.50±16.54 | ||
年龄(岁) | F=0.04 | 0.988 | |
<20 | 151.33±33.55 | ||
20~ | 151.67±15.20 | ||
40~ | 153.43±18.57 | ||
60~ | 150.00±16.97 | ||
民族 | t=2.09 | 0.042 | |
汉族 | 154.78±17.50 | ||
其他民族 | 142.50±11.43 | ||
学历 | t=0.14 | 0.933 | |
小学 | 152.80±11.29 | ||
初中 | 151.42±20.34 | ||
高中或中专 | 150.00±19.74 | ||
大专及以上 | 155.25±13.22 | ||
职业 | F=0.32 | 0.728 | |
工人 | 161.00±9.90 | ||
农民 | 152.35±18.15 | ||
其他(个体户、待业等) | 150.78±16.35 | ||
户口所在地 | t=0.13 | 0.901 | |
城市 | 152.86±10.43 | ||
农村 | 151.97±18.07 | ||
家庭月收入(元) | F=0.63 | 0.602 | |
<1000 | 149.45±12.61 | ||
1000~ | 154.77±20.62 | ||
3000~ | 147.40±13.79 | ||
5000~ | 158.00±11.79 | ||
医保 | t=-0.88 | 0.521 | |
有 | 153.13±17.51 | ||
无 | 147.25±14.66 | ||
是否有药物不良反应 | t=0.43 | 0.670 | |
无 | 153.35±18.41 | ||
有 | 151.15±16.22 | ||
是否规律服药 | t=0.94 | 0.352 | |
是 | 152.61±17.26 | ||
否 | 141.00±1.41 | ||
吸烟量 | t=0.32 | 0.753 | |
不吸烟 | 152.36±17.20 | ||
<1包/d | 149.50±17.41 | ||
饮酒量 | t=-0.24 | 0.809 | |
不饮酒 | 151.98±17.20 | ||
<100ml/d | 155.00±18.38 | ||
因素 | 生命质量总得分(分, | 统计检验值 | P值 |
锻炼情况 | F=0.70 | 0.502 | |
不锻炼 | 146.22±14.59 | ||
每周1~3次 | 153.93±18.26 | ||
每周≥4次 | 151.86±14.63 | ||
BMI (kg/m2) | F=0.88 | 0.421 | |
偏瘦(<18.5) | 147.93±14.89 | ||
正常(18.5~24) | 155.12±18.70 | ||
超重及肥胖(≥24) | 150.00±14.56 | ||
血尿酸a | t=-0.43 | 0.668 | |
不正常 | 152.65±15.87 | ||
正常 | 149.89±22.22 | ||
血尿素氮b | t=-0.55 | 0.589 | |
不正常 | 157.33±21.13 | ||
正常 | 151.74±16.97 | ||
血清肌酐c | t=-0.14 | 0.890 | |
不正常 | 153.25±9.00 | ||
正常 | 152.00±17.68 | ||
天门冬氨酸氨基转移酶d | t=-0.52 | 0.606 | |
不正常 | 154.45±18.05 | ||
正常 | 151.37±16.92 | ||
丙氨酸氨基转移酶e | t=-0.44 | 0.215 | |
不正常 | 144.00±10.83 | ||
正常 | 153.33±17.56 | ||
白细胞计数f | F=0.22 | 0.803 | |
偏低 | 155.50±9.19 | ||
正常 | 152.58±18.40 | ||
偏高 | 148.00±8.15 | ||
血红蛋白g | t=0.03 | 0.976 | |
不正常 | 152.23±14.38 | ||
正常 | 152.06±18.19 | ||
红细胞计数h | F=1.68 | 0.198 | |
偏低 | 149.00±26.87 | ||
正常 | 154.09±17.64 | ||
偏高 | 142.13±8.69 | ||
治疗持续时间 | F=2.62 | 0.084 | |
治疗前(0个月) | 139.33±12.86 | ||
治疗中(1~23个月) | 151.75±16.56 | ||
结束治疗(24个月) | 169.67±17.67 |
变量 | 赋值方法 |
---|---|
X1 性别 | 男=1,女=2 |
X2 年龄(岁) | 0~=1,20~=2,40~=3,60~=4 |
X3 民族 | 汉族=1,其他民族=2 |
X4 学历 | 小学=1,初中=2,高中或中专=3,大专及以上=4 |
X5 职业 | 工人=1,农民=2,其他(个体户、待业等)=3 |
X6 户口所在地 | 城市=1,农村=2 |
X7 家庭月收入 | 1000元以下=1,1000~3000元=2,3000~5000元=3,5000元以上=4 |
X8 有无医保 | 自费=1,有医保=2 |
X9 吸烟情况 | 不吸烟=1,每天1包以下=2 |
X10 饮酒情况 | 不饮酒=1,每天100ml以下=2 |
X11 锻炼情况 | 不锻炼=1,每周锻炼1~3次=2,每周锻炼4次及以上=3 |
X12 药物不良反应 | 无=1,有=2 |
X13 规律服药 | 是=1,否=2 |
X14 BMI (kg/m2) | BMI<18.5=1,18.5≤BMI<24=2,BMI≥24=3 |
X15 血尿酸 | 男性:237.9μmol/L~356.9μmol/L=1;>356.9μmol/L=2 女性:178.4μmol/L~297.4μmol/L=1;>297.4μmol/L=2 |
X16 血尿素氮 | <7.1mmol/L=1, ≥7.1mmol/L=2 |
X17 血清肌酐 | 男性:<106μmol/L=1,>106μmol/L=2 女性:<96μmol/L=1,>96μmol/L=2 |
X18 天门冬氨酸氨基转移酶 | ≤40U/L=1,>40U/L=2 |
X19 丙氨酸氨基转移酶 | ≤40U/L=1,>40U/L=2 |
X20 白细胞计数 | <4×109/L=1, 4×109/L~10×109/L=2,>10×109/L=3 |
X21 血红蛋白 | 男性:<120g/L=1,120g/L~160g/L=2,>160g/L=3 女性:<110g/L=1,110g/L~150g/L=2,>150g/L=3 |
X22 红细胞计数 | 男性:<4×1012/L=1, 4×1012/L~5.5×1012/L=2,>5.5×1012/L=3 女性:<3.5×1012/L=1, 3.5×1012/L~5.0×1012/L=2,>5.0×1012/L=3 |
X23 治疗持续时间 | 0个月=1,1~23个月=2, 24个月=3 |
[1] |
潘陈丽, 徐九云 . 耐多药肺结核患者心理行为的质性研究. 护理学杂志, 2015,30(5):38-40.
doi: 10.3870/hlxzz.2015.05.038 URL |
[2] |
张雪萍, 陈彬 . 社会支持和心理干预在耐多药结核病防治中的应用进展. 中华现代护理杂志, 2017,23(9):1322-1326.
doi: 10.3760/cma.j.issn.1674-2907.2017.09.037 URL |
[3] |
袁保东, 王卫华, 段琼红 , 等. 耐多药肺结核患者生命质量的评价. 中国防痨杂志, 2006,28(3):139-142.
doi: 10.3969/j.issn.1000-6621.2006.03.004 URL |
[4] |
郑如添, 李晓芬 . 耐多药肺结核患者生命质量的变化和影响因素. 中国基层医药, 2008,15(4):570-571.
doi: 10.3760/cma.j.issn.1008-6706.2008.04.022 URL |
[5] | 陈留萍 . 慢性病患者生命质量测定量表体系之肺结核患者生命质量测定量表QLICD-PT研制与应用. 昆明:昆明医科大学, 2012. |
[6] | 陆峰, 王小平, 符剑 , 等. 241例耐多药肺结核患者未治疗原因分析. 江苏预防医学, 2016,27(3):313-314. |
[7] | 郝俊玲 . 实施心理护理干预在耐多药结核病患者中的效果观察. 疾病监测与控制, 2017,11(4):339-340. |
[8] |
马雪雪, 张少茹, 张天华 , 等. 耐多药结核病患者患病体验的定性研究. 中国防痨杂志, 2017,39(5):529-532.
doi: 10.3969/j.issn.1000-6621.2017.05.022 URL |
[9] | 周琳, 王晓萌, 柴程良 , 等. 耐多药肺结核患者心理健康状况及其影响因素调查研究. 中国预防医学杂志, 2017,18(12):894-897. |
[10] | 张琳, 康健, 鲜小萍 . 11例复治涂阳肺结核患者耐药状况及耐药原因分析. 中国防痨杂志, 2018,40(3):292-295. |
[11] |
庞力娟, 肖红卫, 周晋 , 等. 2010—2015年株洲市结核分枝杆菌一线抗结核药物耐药研究. 实用预防医学, 2017,24(5):582-585.
doi: 10.3969/j.issn.1006-3110.2017.05.020 URL |
[12] |
郑如添, 李晓芬 . 耐多药肺结核患者生命质量的变化和影响因素. 中国基层医药, 2008,15(4):570-571.
doi: 10.3760/cma.j.issn.1008-6706.2008.04.022 URL |
[13] |
Maguire GP, Anstey NM, Ardian M , et al. Pulmonary tuberculosis, impaired lung function, disability and quality of life in a high-burden setting. Int J Tuberc Lung Dis, 2009,13(12):1500-1506.
URL pmid: 19919767 |
[14] |
Sharma R, Yadav R, Sharma M , et al. Quality of life of multi drug resistant tuberculosis patients: a study of north India. Acta Med Iran, 2014,52(6):448-453.
doi: 10.1017/S0956536110000271 URL pmid: 25130152 |
[15] |
Horter S, Stringer B, Reynolds L , et al. “Home is where the patient is”: a qualitative analysis of a patient-centred model of care for multi-drug resistant tuberculosis. BMC Health Serv Res, 2014,14:81.
doi: 10.1186/1472-6963-14-81 URL pmid: 3943511 |
[16] | 宋丽君, 章琳, 郑静 . 耐多药肺结核及其患者治疗依从性的护理措施研究进展. 中国防痨杂志, 2018,40(1):111-113. |
[1] | Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397. |
[2] | Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407. |
[3] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[4] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
[5] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[6] | An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438. |
[7] | Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443. |
[8] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[9] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[10] | Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470. |
[11] | Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476. |
[12] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[13] | Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497. |
[14] | Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504. |
[15] | Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||